Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Net Cash Flow (2021 - 2025)

Kezar Life Sciences (KZR) has disclosed Net Cash Flow for 5 consecutive years, with $32.9 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 372.91% to $32.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $30.1 million through Dec 2025, up 376.36% year-over-year, with the annual reading at $30.1 million for FY2025, 376.36% up from the prior year.
  • Net Cash Flow hit $32.9 million in Q4 2025 for Kezar Life Sciences, up from $4.6 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $66.5 million in Q2 2022 to a low of -$40.9 million in Q3 2022.
  • Historically, Net Cash Flow has averaged $2.5 million across 5 years, with a median of $51500.0 in 2021.
  • Biggest YoY gain for Net Cash Flow was 1808.32% in 2022; the steepest drop was 1519.22% in 2022.
  • Year by year, Net Cash Flow stood at $5.8 million in 2021, then crashed by 515.59% to -$24.0 million in 2022, then skyrocketed by 137.26% to $9.0 million in 2023, then fell by 22.23% to $7.0 million in 2024, then soared by 372.91% to $32.9 million in 2025.
  • Business Quant data shows Net Cash Flow for KZR at $32.9 million in Q4 2025, $4.6 million in Q3 2025, and -$2.7 million in Q2 2025.